SynthesisMuscle & nerve2026
Clinical Characteristics and Treatment Management of Seronegative Myasthenia Gravis: A Systematic Review of the Literature.
Synthesis in Muscle & nerve, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Seronegative myasthenia gravis (SNMG) is characterized by the absence of detectable autoantibodies against known MG targets, despite clinical and electrophysiological evidence of a postsynaptic neuromuscular junction disorder. The aim of this systematic review was to better define clinical features, diagnostic clues and treatment outcome of SNMG patients. We conducted a systematic review following PRISMA guidelines, analyzing studies published from 2001 to August 2024 through MEDLINE, Embase, and Cochrane databases. A total of 31 studies (712 patients) with SNMG diagnoses based on clinical features, electrophysiology, pharmacological testing, or treatment response were included. The cohort was predominantly female (473/712, 67%) with a mean age at onset of 42 years. Isolated ocular symptoms were present in 281/500 (56%) patients, with progression to generalized MG in 113/262 (43%) within 2 years from onset. Regarding diagnostic strategies, some studies combined clinical findings consistent with MG and both electrophysiology and pharmacological testing, while others applied a less stringent diagnostic approach, leading to variability in case definitions. Moreover, only 213/448 (48%) patients underwent cell-based assays to confirm the seronegative results after antibody screening, raising concerns of misclassification. Immunotherapy was administered to 271/333 (81%) patients, most commonly corticosteroids combined with immunosuppressants (173/271, 74%). Despite treatment, only 153/394 (39%) achieved the minimal manifestations status, and 52/220 (24%) were classified as refractory. In conclusion, SNMG is a heterogeneous condition with significant diagnostic and therapeutic challenges. Standardized diagnostic criteria, including the use of highly sensitive antibody assays, are needed to improve immunological stratification and optimize therapeutic management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.